Accessibility Menu
 

The Best of 2012: BioDelivery Sciences

BioDelivery Sciences' platform for delivering drugs through the mucous membrane of the inner cheek has certainly stirred investor interest, as the stock is up 428% for the year. That makes it #2 on our list of the best of the best this year in healthcare.

By Brenton Flynn Dec 13, 2012 at 2:07PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.